ZL-2302

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameZL-2302
Drug Alias NameZL-2302
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdHaimen Pharma Inc
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A